| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
723.09(B) |
| Last
Volume: |
3,201,799 |
Avg
Vol: |
3,291,238 |
| 52
Week Range: |
$423.21 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
435,750 |
871,420 |
2,951,506 |
6,211,418 |
| Total Sell Value |
$330,574,311 |
$608,633,217 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
5 |
14 |
46 |
89 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Greene Gabrielle E |
Director |
– • – |
2022-10-17 |
4 |
A |
$332.76 |
$9,983 |
D/D |
30 |
1,029 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2022-10-17 |
4 |
A |
$332.76 |
$9,983 |
D/D |
30 |
177 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-17 |
4 |
S |
$333.76 |
$26,706,632 |
D/D |
(79,624) |
103,541,335 |
|
6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-14 |
4 |
S |
$333.75 |
$1,064,307 |
D/D |
(3,187) |
103,620,959 |
|
6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-12 |
4 |
S |
$333.50 |
$133,400 |
D/D |
(400) |
103,624,146 |
|
1% |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2022-10-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
450 |
6,500 |
|
- |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2022-10-10 |
4 |
AS |
$326.23 |
$214,007 |
D/D |
(656) |
6,950 |
|
2% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-06 |
4 |
S |
$333.89 |
$49,934,082 |
D/D |
(149,264) |
103,624,546 |
|
1% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-09-28 |
4 |
S |
$332.86 |
$34,053,650 |
D/D |
(101,631) |
103,773,810 |
|
-2% |
|
| Luciano Juan R |
Director |
– • – |
2022-09-19 |
4 |
A |
$305.09 |
$14,034 |
D/D |
46 |
14,043 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2022-09-19 |
4 |
A |
$305.09 |
$10,068 |
D/D |
33 |
69,807 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2022-09-19 |
4 |
A |
$305.09 |
$11,288 |
D/D |
37 |
51,968 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2022-09-19 |
4 |
A |
$305.09 |
$9,763 |
D/D |
32 |
1,368 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2022-09-19 |
4 |
A |
$305.09 |
$10,068 |
D/D |
33 |
147 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2022-09-19 |
4 |
A |
$305.09 |
$10,068 |
D/D |
33 |
999 |
|
- |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2022-09-01 |
4 |
AS |
$301.00 |
$301,000 |
D/D |
(1,000) |
5,274 |
|
17% |
|
| Hedley Mary Lynne |
Director |
– • – |
2022-08-15 |
4 |
A |
$313.94 |
$10,046 |
D/D |
32 |
114 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2022-08-15 |
4 |
A |
$313.94 |
$10,046 |
D/D |
32 |
963 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2022-08-15 |
4 |
A |
$313.94 |
$11,302 |
D/D |
36 |
51,771 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2022-08-15 |
4 |
A |
$313.94 |
$14,127 |
D/D |
45 |
13,954 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2022-08-15 |
4 |
A |
$313.94 |
$10,046 |
D/D |
32 |
69,560 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2022-08-15 |
4 |
A |
$313.94 |
$9,732 |
D/D |
31 |
1,332 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2022-08-12 |
4 |
B |
$304.19 |
$199,549 |
D/D |
656 |
62,857 |
2.39 |
19% |
|
| Weems Alonzo |
SVP, ERM & CECO |
• – – |
2022-08-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
530 |
7,606 |
|
- |
|
| Weems Alonzo |
SVP, ERM & CECO |
• – – |
2022-08-10 |
4 |
AS |
$304.50 |
$199,752 |
D/D |
(656) |
8,136 |
|
21% |
|
306 Records found
|
|
Page 5 of 13 |
|
|
20.84 (2.68%) 
